A former employment partner at Norton Rose Fulbright may ask a Federal Court judge to recuse himself from a long-running dispute with the law firm, saying the judge’s previous comments had triggered a “reasonable apprehension” of bias.
Hytera Communications wants the Federal Court to block Motorola from accessing evidence in their patent war covered by Chinese laws prohibiting disclosure of state secrets or compromising the country’s cybersecurity.
A Gold Coast-based derivatives trading firm has lost a defamation case against an online investment forum over critical comments warning potential investors against using the company.
A unit of Fortescue Metals Group has won its bid for emails between Squire Patton Boggs and a unit of electricity provider TransAlta Energy relating to a disputed power purchase agreement, saying privilege was waived when the emails were forwarded to a third party.
The Australian has been hit with a $155,000 fine for publishing an article referring to the criminal convictions of CFMMEU official John Setka despite repeated warnings by prosecutors about prejudicing their blackmail case against the union boss.
A Federal Court judge has expressed her disbelief at a cross claim by generic drug maker Sandoz against Danish multinational H Lundbeck, as the court begins to weigh arguments over damages owed to Lundbeck in the long-running patent case over its blockbuster anti-depressant Lexapro.
Esteemed barrister Michael Wheelahan QC, who recently led Bauer Media in its successful appeal of a $4.5 million defamation award to actor Rebel Wilson, has been appointed as a Federal Court judge.
Take-Two interactive has won an injunction blocking a Grand Theft Auto gamer from distributing software that allows users to access restricted features of the popular game, a month after reaching a settlement with a gamer in a separate copyright case.
Preparations for a December trial between Merck Sharp & Dohme Corporation and Wyeth over four patents for the pneumococcal disease vaccine are underway, and a panel of experts will feature prominently in the high-stakes hearing over the world’s best-selling vaccine.
Shareholders in a class action against Sirtex have secured an order forcing the life sciences company to notify them of any plan that would see its $128 million in liquid assets drop below $80 million.